Fredag 4 Juli | 06:00:49 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-11-27 08:00 Kvartalsrapport 2025-Q3
2025-08-28 08:00 Kvartalsrapport 2025-Q2
2025-06-25 - X-dag ordinarie utdelning PRLD 0.00 SEK
2025-06-24 - Årsstämma
2025-06-10 - Extra Bolagsstämma 2025
2025-05-30 - Kvartalsrapport 2025-Q1
2025-02-28 - Bokslutskommuniké 2024
2024-11-27 - Kvartalsrapport 2024-Q3
2024-08-28 - Kvartalsrapport 2024-Q2
2024-05-27 - Årsstämma
2024-05-17 - Kvartalsrapport 2024-Q1
2024-05-15 - X-dag ordinarie utdelning PRLD 0.00 SEK
2024-02-21 - Bokslutskommuniké 2023
2023-11-27 - Extra Bolagsstämma 2023
2023-11-27 - Kvartalsrapport 2023-Q3
2023-08-29 - Kvartalsrapport 2023-Q2
2023-05-12 - X-dag ordinarie utdelning PRLD 0.00 SEK
2023-05-11 - Årsstämma
2023-05-11 - Kvartalsrapport 2023-Q1
2023-02-21 - Bokslutskommuniké 2022
2022-11-30 - Kvartalsrapport 2022-Q3
2022-08-29 - Kvartalsrapport 2022-Q2
2022-08-04 - Extra Bolagsstämma 2022
2022-05-23 - X-dag ordinarie utdelning PRLD 0.00 SEK
2022-05-20 - Årsstämma
2022-05-20 - Kvartalsrapport 2022-Q1
2022-02-22 - Bokslutskommuniké 2021
2021-11-23 - Kvartalsrapport 2021-Q3
2021-08-31 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning PRLD 0.00 SEK
2021-05-05 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-24 - Bokslutskommuniké 2020
2020-11-17 - Kvartalsrapport 2020-Q3
2020-08-28 - Kvartalsrapport 2020-Q2
2020-05-21 - X-dag ordinarie utdelning PRLD 0.00 SEK
2020-05-20 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-20 - Kvartalsrapport 2019-Q3
2019-08-28 - Kvartalsrapport 2019-Q2
2019-05-16 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-05-10 - X-dag ordinarie utdelning PRLD 0.00 SEK
2018-11-20 - Kvartalsrapport 2018-Q3
2018-08-28 - Kvartalsrapport 2018-Q2
2018-05-17 - X-dag ordinarie utdelning PRLD 0.00 SEK
2018-05-16 - Årsstämma
2018-05-16 - Kvartalsrapport 2018-Q1
2018-02-14 - Bokslutskommuniké 2017
2017-11-23 - Kvartalsrapport 2017-Q3
2017-08-25 - Kvartalsrapport 2017-Q2
2017-05-22 - X-dag ordinarie utdelning PRLD 0.00 SEK
2017-05-19 - Årsstämma
2017-05-19 - Kvartalsrapport 2017-Q1

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriMedicinteknik
Prolight Diagnostics utvecklar testsystem inom POCT (Point of care testning). Testerna används utanför sjukhuslaboratorium för att möjliggöra snabba bedömningar av patienters hälsa. Bolagets POCT-Plattform är i utveckling med avsikt att mäta flera biomarkörer samtidigt. En viktig del i arbetet är således att korta ner tiden för provresultaten, särskilt viktigt för patienter med hjärtbesvär. Bolaget grundades år 1999 och har sitt huvudkontor i Lund.
2025-07-02 08:05:00

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.

Prolight Diagnostics AB (publ) (“Prolight” or the “Company”) hereby announces the final outcome of the rights issue of shares, which the board of directors resolved on May 21, 2025, and later approved by an Extraordinary General Meeting on June 10, 2025 (the “Rights Issue”). The Rights Issue was fully subscribed whereas approximately 70.2 percent was subscribed with subscription rights and approximately 29.8 percent was subscribed without subscription rights. Through the Rights Issue, the Company will receive net proceeds of approximately SEK 100.3 million before issue costs and set-offs.

CEO Ulf Bladin comment on the outcome
We would like to extend our sincere thanks to our shareholders for the strong support you have shown, and warmly welcome our new investors. Your commitment has enabled a cost-effective financing without the need for underwriters. The significant participation from our board, management, and employees, who together invested approx. SEK 10 million, as well as our instrument contract manufacturing partner, ITL, contributing approx. SEK 9.9 million, underscores the shared confidence in our strategy and future. The capital raised through this rights issue enables us to optimize, verify, and complete the development of our point-of-care system Psyros, finalize validated pilot production lines for both cartridges and instruments, accelerate business development efforts aimed at securing a commercial partnership and prepare for market access, initiate the clinical performance study and regulatory processes, as well as to build inventory ahead of commercial launch of Psyros in Europe”, said Ulf Bladin, CEO at Prolight Diagnostics.

Preliminary outcome of the Rights Issue
The subscription period in the Rights Issue ended on June 30, 2025. The final outcome shows that 351 805 515 shares, corresponding to approximately 70.2 percent of the Rights Issue, have been subscribed for with subscription rights in the Rights Issue. In addition, applications have been received to subscribe for 149 686 965 shares without subscription rights, corresponding to approximately 29.8 percent of the Rights Issue. Thus, the final outcome shows that a total of 501,492,480 shares has been subscribed for in the Rights Issue, with and without subscription rights, corresponding to a subscription rate of 100 percent. The Rights Issue is thus fully subscribed.

Allocation of shares subscribed without subscription rights
Allotment of shares subscribed for without subscription rights has been made in accordance with the principles set out in the information document published by the Company on June 13, 2025, in connection with the Rights Issue. Notice of such allotment will be announced separately through a settlement note. Nominee-registered shareholders will receive notification of allotment in accordance with instructions from the respective nominee.

Trading in paid subscribed shares (“BTA”)
The last day of trading in BTAs is expected to be July 16, 2025. Trading in the new shares subscribed for with and without subscription rights is expected to commence on Nordic SME Sweden on or around July 18, 2025.

Shares and share capital
Through the Rights Issue, the total number of shares in the Company will increase by 501,492,480 shares, from 702,089,478 shares to 1,203,581,958 shares, and the share capital will increase by SEK 50,149,248.00, from SEK 70,208,947.80 to SEK 120,358,195.80. This corresponds to a dilution effect of approximately 41.7 percent of the total number of shares and votes in the Company.

Advisors
Mangold Fondkommission AB is financial advisor and Advokatfirman Lindahl KB is legal advisor to the Company in connection with the Rights Issue.